Staff

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease

Mitapivat demonstrated statistically significant improvement in hemoglobin response compared with placebo, with rapid onset and durable effectsNew analyses showed patients...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat...

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus daratumumab with or without pomalidomide showed progression-free survival of up to 81.3% and overall survival of up to 89.2% at 24...

Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage...

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1...

Monadnock Community Hospital Strengthens Cyber Resilience Under CEO Richard Scheinblum’s Leadership with Deployment of WireX Platform

Rural healthcare leader adopts advanced cyber investigation capabilities to accelerate incident response, improve visibility, and reduce organizational riskPETERBOROUGH, N.H., June...

WallachBeth Capital Announces Closing of Healthcare Triangle, Inc. Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of Approximately $3.6 Million

Healthcare Triangle, Inc. Announces Closing of Private Placement Offering of Original Issue Discount Senior Convertible Promissory Notes for Gross Proceeds of Approximately $3.6 Million

PLEASANTON, Calif., June 12, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital...

error: Content is protected !!